Biotechnology

Biodexa Pharmaceuticals

Biodexa Pharmaceuticals released FY2025 Annual Earnings on March 27, 2026 (EST) with actual revenue of USD 0 and EPS of USD -77.9417

Biodexa Pharmaceuticals released FY2025 Q4 earnings on March 27, 2026 (EST), with actual revenue of USD 0 and EPS of USD -1.6945

Biodexa Pharmaceuticals released FY2025 Q3 earnings on March 27, 2026 (EST) with actual revenue of USD 0 and EPS of USD -10.2534

Biodexa Pharmaceuticals released FY2025 9-month earnings on March 27 (EST), actual revenue USD 0, actual EPS USD -110.6172

Biodexa Pharmaceuticals receives EMA approval for the third phase Serenta clinical trial for Familial Adenomatous Polyposis

Biodexa Pharmaceuticals released FY2025 Semi-Annual earnings on September 12 EST, with actual revenue of USD 0 and EPS of USD -100.3637

Biodexa Pharmaceuticals released FY2025 Q2 earnings on September 12 (EST), actual revenue USD 0, actual EPS USD -10.3233

Biodexa Pharmaceuticals released FY2025 Q1 earnings on September 12, 2025 (EST) with actual revenue of USD 0 and EPS of USD -48.7476

Biodexa Submits Phase 3 Clinical Trial Application for FAP to EMA

Biodexa Launches Tolimidone Phase 2a Clinical Trial

Biodexa Enrolls First Patient in Phase 2 Tolimidone Study for Type 1 Diabetes

Biodexa Pharmaceuticals and Emtora Biosciences Receive Additional CPRIT Funding

Biodexa Pharmaceuticals Obtains Orphan Drug Designation and Launches FAP Phase III Clinical Trial

Biodexa Pharmaceuticals to Hold Shareholder Meeting to Vote on Three Strategic Resolutions

Biodexa Pharmaceuticals released FY2024 9 Months Earnings on April 11, 2025 (EST), actual revenue USD 0, actual EPS USD -122.2056

Biodexa Pharmaceuticals released FY2024 annual earnings on April 11, 2025 (EST), with actual revenue of USD 0 and EPS of USD -14.799

Biodexa Pharmaceuticals released FY2024 Q4 earnings on April 11, 2025 (EST) with actual revenue of USD 0 and EPS of USD -114.6179

Biodexa Pharmaceuticals released FY2024 Q3 earnings on April 11, 2025 (EST) with actual revenue of USD 0 and EPS of USD -122.2056

Biodexa Reports Positive Progress in Discussions with FDA on eRapa for FAP

Biodexa Pharmaceuticals released FY2024 Semi-Annual earnings on September 26 (EST), actual revenue USD 0 (forecast USD 16.43 K), actual EPS USD 0

InMed Pharmaceuticals

AMPLITECH GROUP INC. USD0.001 S/R 20/11/26 SER B

Amesite

CN Energy

AMPLITECH GROUP INC. COM USD0.001 (S/R 18/07/2026)

NextNRG

Meiwu Tech

Generation Income Properties

MetaVia

OceanPal

ALNY

BDRX

Alnylam Pharma pre-market rose 9.59%; Biodexa Pharmaceuticals pre-market fell 9.38%; Entravision Communications pre-market rose 74.87%; Easy Electric pre-market rose 68.40%; Avalo Therapeutics pre-market rose 44.96%

Price Alert

Alnylam Pharma

Entravision Comm

EZGO Tech

Avalo Therapeutics

Pre-market hot trades in US stocks: Alnylam Pharma up 9.59% pre-market; Biodexa Pharmaceuticals down 9.38% pre-market

Biodexa Pharmaceuticals fell 8.04% in after-hours trading; BeiGene fell 1.73% in after-hours trading, with a transaction volume of USD 495,000; Recursion Pharmaceuticals had a transaction volume of USD 211,200; Amgen fell 0.01% in after-hours trading, with a transaction volume of USD 97,600

Beigene

Recursion Pharmaceuticals

Amgen

U.S. stock night market volatility: Biodexa Pharmaceuticals fell 8.04% in the night market, market volatility intensified, and capital flow attracted attention

EDAP

01876

HSBA

HSBC

European equities traded in the US as American depositary receipts rose 0.27% to 1,794.86 on the S&P Europe Select ADR Index. Notable gainers included Anheuser-Busch InBev (up 9%) and EDAP TMS (up 3%). Decliners included Sequans Communications (down 9.7%) and Criteo (down 3.9%). In the UK, Biodexa Pharmaceuticals surged 32%, while HSBC fell 5%.

Fidelity

EDAP TMS

BUD APAC

HSBC Holdings Plc

European Equities Traded in the US as American Depositary Receipts Higher in Tuesday Trading

EMBC

CLRB

In Tuesday's pre-market session, Cellectar Biosciences (CLRB) saw a significant gain of 45.0%, reaching $4.1, while Viridian Therapeutics (VRDN) rose by 27.38% to $17.91. Cytokinetics (CYTK) increased by 26.95% to $83.86. Other gainers included Biodexa Pharmaceuticals (BDRX) and Edgewise Therapeutics (EWTX). Conversely, GeneDx Holdings (WGS) experienced a sharp decline of 41.9% to $39.48, followed by Embecta (EMBC) down 31.9% to $6.3. Other losers included Picard Medical (PMI) and CNS Pharmaceuticals (CNSP).

benzinga_article

Embecta

Cellectar Bioscience

Cytokinetics

Edgewise Therapeutics

Viridian Therapeutics

GeneDx

CNS Pharma

Picard Medical

Health Care Select Sector SPDR

iShares Biotechnology ETF

iShares US Medical Devices

ALPS Medical Breakthrough

Invesco Nasdaq Biotechnology ETF

iShares US Pharma

Proshares Ultra Nasdaq Biotech

Invesco Biotechnology & Genome ETF

VG Health

iShares Global Healthcare

First Trust NYSE Arca Biotech Index Fd

Direxion Pharma & Medical Bull 3X

Direxion S&P Biotech Bull 3X

Ark Genomic Revolution ETF

SPDR S&P Biotech

iShares US Healthcare Providers

iShares Genomics Immunology and Healthcare ETF

VanEck Biotech ETF

SPDR S&P Health Equip

Regentis Biomaterials

Akanda

Lunai Bioworks

GeneDx - CW27

12 Health Care Stocks Moving In Tuesday's Pre-Market Session

SNYNF

CRTO

European equities traded in the US as American depositary receipts eased, with the S&P Europe Select ADR Index down 0.1% to 1,801.52. Notable gainers included Nokia (up 6.4%) and Sanofi (up 2.5%), while SAP and Criteo led the decliners, falling 5% and 3.5%, respectively. In the UK, Silence Therapeutics rose 4.8%, while Biodexa Pharmaceuticals dropped 6.4%.

fidelity

Sanofi

Criteo SA

European Equities Traded in US as ADRs Ease in Thursday Trading

EFOI

Energy Focus pre-market up 13.25%; Biodexa Pharmaceuticals pre-market down 7.14%; Local Bounti pre-market up 61.69%; Click Holdings/BVI pre-market up 51.36%; SciSparc pre-market up 48.46%

Energy Focus

Pre-market hot trades in US stocks: Energy Focus up 13.25% in pre-market; Biodexa Pharmaceuticals down 7.14% in pre-market

AIXI

TNMG

In the past hour, the overall market in the U.S. stock market has shown a clear divergence, with technology and healthcare sectors performing particularly well. Xiao I saw an increase of 15.07%, attracting market attention, as it seems that short-term funds are confident about its future prospects. Meanwhile, Biodexa Pharmaceuticals faced a significant setback, with a decline of 18.86%, indicating that investors have raised doubts about its fundamentals. Overall, market sentiment has been quite volatile, with short-term enthusiasm concentrated on a few strong stocks, and capital flows are constantly switching. The stock with the largest movement in the past hour, Xiao I, performed impressively in the market, with an increase of 15.07%. The strong rebound of this stock seems to have attracted a large influx of short-term funds, driving its price up rapidly, and market sentiment has thus become more active. Investors are full of expectations for its future technological applications, and trading enthusiasm has clearly increased in the short term. Strong stocks: 1. Humana: up 11.37%, recent market response to its new products has been positive, attracting considerable capital attention. 2. Sky Quarry: up 8.60%, the company's layout in the environmental protection field has sparked investor enthusiasm, with noticeable short-term capital inflow. 3. Unitedhealth: up 6.86%, performing outstandingly in the healthcare sector, with optimistic market expectations for its performance. 4. LZ Tech - B: up 4.68%, the stock's progress in technological innovation has drawn investor attention, with increased activity in the short term

Xiao I

TNL Mediagene

Humana

ABVC BioPharma

Sky Quarry

Perfect Moment

Moolec Science SA

Lion

Unitedhealth

LZ Tech - B

Maxeon Solar Tech

MAXEON SOLAR TECHNOLOGIES LTD

U.S. stock market movement update: Xiao I surged 15.07%, Biodexa Pharmaceuticals plummeted 18.86%

In the past hour, the overall market in the US stock market has shown a clear divergence, with technology and healthcare sectors performing particularly well. Xiao I led the way with a 16.56% increase, attracting significant short-term capital attention, indicating that market enthusiasm for the artificial intelligence sector remains high. Meanwhile, Biodexa Pharmaceuticals and TNL Mediagene experienced substantial declines, dropping 14.47% and 12.79% respectively, reflecting cautious sentiment among investors towards the biopharmaceutical sector. Overall, market volatility has increased, short-term enthusiasm has clearly risen, and capital flows are continuously adjusting. The most notable stock in the past hour was Xiao I, which performed impressively with a 16.56% increase. The strong rebound of this stock seems to be attributed to market recognition of its technological advancements, with the influx of short-term capital rapidly driving up its stock price and boosting the activity of related technology stocks. Strong stocks include: 1. Sky Quarry: up 11.40%, as recent market attention on its sustainable development projects has driven up its stock price. 2. Humana: up 10.71%, with the company's innovative products in the healthcare sector sparking investor enthusiasm and active short-term capital involvement. 3. Turbo Energy SA: up 7.17%, as the trend of energy transition has attracted significant capital inflow, resulting in outstanding performance

Turbo Energy SA

Faraday Future Intelligent Electric

U.S. stock market movement update: Xiao I surged 16.56%, Sky Quarry and Humana followed closely, while Biodexa Pharmaceuticals plummeted 14.47%

In the past hour, the overall market in the U.S. stock market has shown a clear divergence, with technology stocks and energy stocks performing actively, and the capital flow seems to lean more towards short-term hot spots. Small-cap stocks and thematic stocks have experienced significant volatility, especially the strong rise of Xiao I and Sky Quarry, which has attracted considerable attention from short-term funds. Meanwhile, some pharmaceutical stocks such as Biodexa Pharmaceuticals and TNL Mediagene have faced significant selling pressure, reflecting the complexity of market sentiment. Overall, the short-term heat is changing frequently, and the market pace is relatively fast. In the past hour, the stock with the largest abnormal movement, Xiao I, rose by 15.43%, attracting strong attention in the market, with rapid capital inflow and heightened short-term sentiment, suggesting potential for further upward movement. Sky Quarry also performed well, with an increase of 11.80%, possibly due to the market's optimistic expectations for its future development prospects. Strong stocks include: 1. Humana: up 10.45%, with recent market attention on its product line and noticeable capital inflow. 2. Turbo Energy SA: up 8.47%, with short-term funds actively participating driven by the energy sector. 3. Battalion Oil: up 7.08%, benefiting from the rebound in oil prices, with optimistic market sentiment. 4. Unitedhealth: up 6.62%, as the healthcare sector continues to be favored by investors, with stable capital inflow

Battalion Oil

U.S. stock market movement report: Xiao I surged 15.43%, TNL Mediagene plummeted 14.35%

Biodexa Pharmaceuticals(BDRX.US)